Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and abnormal fatigability due to the antibodies against postsynaptic receptors. Despite the individual discrepancy, patients with MG share common muscle weakness, autoimmune dysfunction, and immunosuppressive treatment, which predispose them to infections that can trigger or exacerbate MG. Vaccination, as a mainstay of prophylaxis, is a major management strategy. However, the past years have seen growth in vaccine hesitancy, owing to safety and efficacy concerns. Ironically, vaccines, serving as an essential and effective means of defense, may induce similar immune cross-reactivity to what they are meant to prevent. Herein, we outline the progress in vaccination, review the current status, and postulate the clinical association among MG, vaccination, and immunosuppression. We also address safety and efficacy concerns of vaccination in MG, in relation to COVID-19. Since only a handful of studies have reported vaccination in individuals with MG, we further review the current clinical studies and guidelines in rheumatic diseases. Overall, our reviews offer a reference to guide future vaccine clinical decision-making and improve the management of MG patients.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccines, Immunosuppression, Autoimmune, myasthenia gravis, neuromuscular disease, infection prophylaxis, 【초록키워드】 Rheumatic diseases, Efficacy, Vaccine, vaccination, Infection, Vaccine hesitancy, immune, Prophylaxis, cross-reactivity, Autoimmune disease, management, Patient, receptors, patients, association, clinical study, Immunosuppressive treatment, dysfunction, growth, individual, weakness, discrepancy, Defense, offer, Prevent, effective, fatigability, IMPROVE, reported, characterized, induce, exacerbate, the antibody, 【제목키워드】 Myasthenia,